Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities

  • Wouter A. P. BreemanEmail author
  • Marion de Jong
  • Theo J. Visser
  • Jack L. Erion
  • Eric P. Krenning
Occasional Survey


DOTA-conjugated peptides, such as [DOTA0,Tyr3]octreotide (DOTATOC) and [DOTA0,Tyr3]octreotate (DOTA-tate), can be labelled with radionuclides such as 90Y, 111In and 177Lu. These radiolabelled somatostatin analogues are used for peptide receptor radionuclide therapy (PRRT). Radioligands for PRRT require high specific activities. However, although these radionuclides are produced without addition of carrier, contaminants are introduced during production and as decay products. In this study, parameters influencing the kinetics of labelling of DOTA-peptides were investigated and conditions were optimised to obtain the highest achievable specific activity. The effects of contaminants were systematically investigated, concentration dependently, in a test model mimicking conditions for labelling with minimal molar excess of DOTA-peptides over radionuclide. Kinetics of labelling of DOTA-peptides were optimal at pH 4–4.5; pH <4 strongly slowed down the kinetics. Above pH 5, reaction kinetics varied owing to the formation of radionuclide hydroxides. Labelling with 90Y and 177Lu was completed after 20 min at 80°C, while labelling with 111In was completed after 30 min at 100°C. The effects of contaminants were systematically categorised, e.g. Cd2+ is the target and decay product of 111In, and it was found to be a strong competitor with 111In for incorporation in DOTA. In contrast, Zr4+ and Hf4+, decay products of 90Y and 177Lu, respectively, did not interfere with the incorporation of these radionuclides. The following conclusions are drawn: (a) DOTA-peptides can be radiolabelled at high specific activity; (b) reaction kinetics differ for each radionuclide; and (c) reactions can be hampered by contaminants, such as target material and decay products.


DOTA Radiolabelling Specific activity 



The technical assistance of Deborah Thoonsen and Erik de Blois is greatly acknowledged.


  1. 1.
    Otte A, Jermann E, Behe M, et al. DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997; 24:792–795.Google Scholar
  2. 2.
    Erion J, Bugaj JE, Schmidt MA, Wilhelm RR, Srinivasan A. High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model. J Nucl Med 1999; 40:223p.Google Scholar
  3. 3.
    Krenning EP, Valkema R, Kooij PP, et al. The role of radioactive somatostatin and its analogues in the control of tumor growth. Recent Results Cancer Res 2000; 153:1–13.Google Scholar
  4. 4.
    Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421–1429.Google Scholar
  5. 5.
    Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med 2000; 41:1704–1713.Google Scholar
  6. 6.
    Kwekkeboom DJ, Bakker WH, Kooij PP, et al. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001; 28:1319–1325.Google Scholar
  7. 7.
    Jansen JB, Jebbink MC, Douglas BR, Lamers CB. Effect of loxiglumide (CR-1505) on bombesin- and meal-stimulated plasma cholecystokinin in man. Eur J Clin Pharmacol 1990; 38:367–370.Google Scholar
  8. 8.
    Bunemann M, Hosey MM. G-protein coupled receptor kinases as modulators of G-protein signalling. J Physiol 1999; 517:5–23.Google Scholar
  9. 9.
    Szilagyi E TE, Kovacs Z, Platzek J, Radüchel B, Brücher E. Equilibria and formation kinetics of some cyclen derivative complexes of lanthanides. Inorganica Chemica Acta 2000; 298:226–234.Google Scholar
  10. 10.
    Moerlein SM Welch MJ. The chemistry of gallium and indium as related to radiopharmaceutical production. Int J Nucl Med Biol 1981; 8:2772–2787.Google Scholar
  11. 11.
    Kukis DL, DeNardo SJ, DeNardo GL, O'Donnell RT, Meares CF. Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med 1998; 39:2105–2110.Google Scholar
  12. 12.
    Liu S, Cheung E, Ziegler MC, Rajopadhye M, Edwards DS. (90)Y and (177)Lu labeling of a DOTA-conjugated vitronectin receptor antagonist useful for tumor therapy. Bioconjug Chem 2001; 12:559–568.Google Scholar
  13. 13.
    Bakker WH, Krenning EP, Breeman WA, et al. In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man J Nucl Med 1991; 32:1184–1189 [published erratum appears in J Nucl Med 1991; 32:1999] [see comments].Google Scholar
  14. 14.
    Smith-Jones PM, Stolz B, Albert R, et al. Synthesis and characterisation of [90Y]-Bz-DTPA-oct: a yttrium-90- labelled octreotide analogue for radiotherapy of somatostatin receptor- positive tumours. Nucl Med Biol 1998; 25:181–188.Google Scholar
  15. 15.
    Breeman W, Erion JL, Bakker, WH, Visser, TJ, Krenning, EP, de Jong, M. Optimizing conditions for radiolabeling of DOTA-peptides with90Y, 111In, and 177Lu at high specific activities. Eur J Nucl Med 2002; 29:P690.Google Scholar
  16. 16.
    NIST. NIST critically selected stability constants of metal complexes. A.E. Martell, ed.Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Wouter A. P. Breeman
    • 1
    Email author
  • Marion de Jong
    • 1
  • Theo J. Visser
    • 2
  • Jack L. Erion
    • 3
  • Eric P. Krenning
    • 1
    • 2
  1. 1.Department of Nuclear MedicineErasmus MC RotterdamRotterdamThe Netherlands
  2. 2.Department of Internal MedicineErasmus MC RotterdamRotterdamThe Netherlands
  3. 3.BioSynthemaSt. LouisUSA

Personalised recommendations